Americas

Argentina

Spanish

Brazil

Portuguese

Canada

Chile

Spanish

Colombia

Spanish

Mexico

Spanish

Peru

Spanish

United States

English

Asia Pacific

Europe

Austria

German

Belgium

Czech Republic

Czech

Denmark

Norwegian

Finland

Finnish

France

French

Germany

German

Greece

Greek

Hungary

Hungarian

Ireland

English

Italy

Italian

Luxembourg

English

Netherlands

Norway

Norwegian

Poland

Poland

Portugal

Portuguese

Romania

Romanian

Spain

Spanish

Sweden

Swedish

Switzerland

United Kingdom

English

Middle East

Israel

Hebrew

Saudi Arabia

Turkey

Turkish

United Arab Emirates

Other

Other Markets

Distributor Markets
Our Medicines
Search
Search

Transparency

We believe in providing an open environment to help build a foundation of trust and respect among our colleagues, healthcare professionals, patients, stockholders, and the public. Making information available is important as we continue to operate our business to the highest standards, and in keeping with current laws and regulations.

We are firmly focused on Our Mission and take our responsibility for transparency seriously. Sustainability reporting is a clear example of an area in which we will continue to work to increase transparency as we show progress towards our Sustainability 2020 Goals.

At Bristol Myers Squibb we work in partnership with lots of organisations to meet the needs of patients and the NHS. Bristol Myers Squibb is committed to working in partnership with others in a way which is fully compliant with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. Our objective is to act transparently with all stakeholders and the community at large.

UK Transparency

Bristol Myers Squibb is widely recognised for excellence in providing some of the world’s most important medicines for patients. At the same time, we strive to be transparent by providing information about treatments we are studying, whether they are investigational compounds, or new indications for existing marketed products.

At Bristol Myers Squibb we work in partnership with lots of organisations to meet the needs of patients and the NHS. Bristol Myers Squibb is committed to working in partnership with others in a way which is fully compliant with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. Our objective is to act transparently with all stakeholders and the community at large.

Methodologies on What We Are Disclosing

For BMS Methodology document please see the Disclosure UK database hosted on the website of the ABPI

Disclosure Reports

Patient Organisations

To view the latest information on payments Bristol Myers Squibb has made to support the work of patient organisations, please click here. Information on payments made in 2023 are available here and 2022 available here. For information on EFPIA - Patient Advocacy Group Methodology please click here.

Members of the Public

To view the latest information on payments Bristol Myers Squibb has made when working with Members of the Public (including patients and journalists), please click here. Information on payments made in 2023 are available here and 2022 available here.

Health Professionals and Healthcare Organisations

For transparency reports covering the latest three years of reportable data for Health Professional and Healthcare Organisations, see the Disclosure UK database hosted on the website of the ABPI.

For information on our methodological approach for HCPs, HCOs and Members of the Public (including patients and journalists), please click here.

If you have a question about Transfers of Value reported by Bristol Myers Squibb, contact us via transparency_EU@bms.com


NO-GB-2500083
June 2025

AltStyle によって変換されたページ (->オリジナル) /